Company registration number 08626530 (England and Wales)
DR ISSING LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
PAGES FOR FILING WITH REGISTRAR
DR ISSING LTD
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 7
DR ISSING LTD
BALANCE SHEET
AS AT 31 MARCH 2025
31 March 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible fixed assets
4
1,175
1,589
Fixed asset investments
5
537,265
431,145
538,440
432,734
Current assets
Debtors
6
439
8,537
Cash at bank and in hand
284,770
297,858
285,209
306,395
Creditors: amounts falling due within one year
7
(36,321)
(42,779)
Net current assets
248,888
263,616
Total assets less current liabilities
787,328
696,350
Provisions for liabilities
(294)
(397)
Net assets
787,034
695,953
Capital and reserves
Called up share capital
8
2
2
Profit and loss reserves
787,032
695,951
Total equity
787,034
695,953

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

DR ISSING LTD
BALANCE SHEET (CONTINUED)
AS AT 31 MARCH 2025
31 March 2025
- 2 -
The financial statements were approved by the board of directors and authorised for issue on 18 November 2025 and are signed on its behalf by:
Dr W Issing
Director
Company Registration No. 08626530
DR ISSING LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
- 3 -
1
Accounting policies
Company information

Dr Issing Ltd is a private company limited by shares incorporated in England and Wales. The registered office is C/O RMT Accountants & Business Advisors, Gosforth Park Avenue, Newcastle upon Tyne, NE12 8EG.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of certain financial instruments at fair value. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover represents amounts receivable for medical services provided. Turnover is attributable to the continuing principal activity of the company and arose wholly within the United Kingdom.

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Computer equipment
25% straight line
1.4
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

1.5
Cash and cash equivalents

Cash at bank and in hand are basic financial assets and include cash in hand and deposits held at call with banks.

1.6
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost.

DR ISSING LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 4 -
Other financial assets

Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

1.7
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.8
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

1.9
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense.

1.10
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

DR ISSING LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 5 -
2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Total
2
2
3
Taxation
2025
2024
£
£
Current tax
UK corporation tax on profits for the current period
30,962
34,388
Deferred tax
Origination and reversal of timing differences
(103)
365
Total tax charge
30,859
34,753
4
Tangible fixed assets
Computer equipment
£
Cost
At 1 April 2024 and 31 March 2025
2,086
Depreciation
At 1 April 2024
497
Depreciation charged in the year
414
At 31 March 2025
911
Carrying amount
At 31 March 2025
1,175
At 31 March 2024
1,589
5
Fixed asset investments
2025
2024
£
£
Listed investments
537,265
431,145
DR ISSING LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
5
Fixed asset investments
(Continued)
- 6 -
Movements in fixed asset investments
Investments other than loans
£
Cost or valuation
At 1 April 2024
431,145
Additions
262,315
Valuation changes
85,737
Disposals
(241,932)
At 31 March 2025
537,265
Carrying amount
At 31 March 2025
537,265
At 31 March 2024
431,145
6
Debtors
2025
2024
Amounts falling due within one year:
£
£
Other debtors
439
8,537
7
Creditors: amounts falling due within one year
2025
2024
£
£
Corporation tax
30,962
34,388
Other creditors
5,359
8,391
36,321
42,779
8
Called up share capital
2025
2024
£
£
Ordinary share capital
Issued and fully paid
2 Ordinary shares of £1 each
2
2
DR ISSING LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 7 -
9
Related party transactions

The following amounts were outstanding at the reporting end date:

2025
2024
Amounts due to related parties
£
£
Directors
1,758
3,110

The following amounts were outstanding at the reporting end date:

Other information

There are no set terms as to the repayment of this balance or interest accrued thereon.

2025-03-312024-04-01falsefalsefalse18 November 2025CCH SoftwareCCH Accounts Production 2025.300No description of principal activityDr W IssingMrs G M Duerr086265302024-04-012025-03-31086265302025-03-31086265302024-03-3108626530core:ComputerEquipment2025-03-3108626530core:ComputerEquipment2024-03-3108626530core:CurrentFinancialInstruments2025-03-3108626530core:CurrentFinancialInstruments2024-03-3108626530core:ShareCapital2025-03-3108626530core:ShareCapital2024-03-3108626530core:RetainedEarningsAccumulatedLosses2025-03-3108626530core:RetainedEarningsAccumulatedLosses2024-03-3108626530core:ShareCapitalOrdinaryShareClass12025-03-3108626530core:ShareCapitalOrdinaryShareClass12024-03-3108626530bus:Director12024-04-012025-03-3108626530core:ComputerEquipment2024-04-012025-03-31086265302023-04-012024-03-3108626530core:UKTax2024-04-012025-03-3108626530core:UKTax2023-04-012024-03-3108626530core:ComputerEquipment2024-03-3108626530core:CurrentFinancialInstrumentscore:WithinOneYear2025-03-3108626530core:CurrentFinancialInstrumentscore:WithinOneYear2024-03-3108626530bus:PrivateLimitedCompanyLtd2024-04-012025-03-3108626530bus:SmallCompaniesRegimeForAccounts2024-04-012025-03-3108626530bus:FRS1022024-04-012025-03-3108626530bus:AuditExemptWithAccountantsReport2024-04-012025-03-3108626530bus:Director22024-04-012025-03-3108626530bus:FullAccounts2024-04-012025-03-31xbrli:purexbrli:sharesiso4217:GBP